Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ALEMBIC PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
ALEMBIC PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 792 | 319 | - | |
Low | Rs | 463 | 230 | - | |
Sales per share (Unadj.) | Rs | 287.6 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 17.4 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 31.4 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 8.00 | 0 | - | |
Avg Dividend yield | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 222.3 | 74.5 | - | |
Shares outstanding (eoy) | m | 196.56 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.2 | 2.9 | 75.5% | |
Avg P/E ratio | x | 36.1 | -11.5 | -314.2% | |
P/CF ratio (eoy) | x | 20.0 | -13.9 | -144.2% | |
Price / Book Value ratio | x | 2.8 | 3.7 | 76.6% | |
Dividend payout | % | 46.0 | 0 | - | |
Avg Mkt Cap | Rs m | 123,402 | 46,340 | 266.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 11,691 | 2,908 | 402.0% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 56,526 | 16,016 | 352.9% | |
Other income | Rs m | 30 | 112 | 27.1% | |
Total revenues | Rs m | 56,557 | 16,128 | 350.7% | |
Gross profit | Rs m | 6,772 | -2,775 | -244.0% | |
Depreciation | Rs m | 2,754 | 691 | 398.5% | |
Interest | Rs m | 502 | 434 | 115.6% | |
Profit before tax | Rs m | 3,546 | -3,788 | -93.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 126 | 237 | 53.3% | |
Profit after tax | Rs m | 3,420 | -4,036 | -84.7% | |
Gross profit margin | % | 12.0 | -17.3 | -69.1% | |
Effective tax rate | % | 3.6 | -6.2 | -56.9% | |
Net profit margin | % | 6.1 | -25.2 | -24.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 29,139 | 11,730 | 248.4% | |
Current liabilities | Rs m | 16,408 | 6,600 | 248.6% | |
Net working cap to sales | % | 22.5 | 32.0 | 70.3% | |
Current ratio | x | 1.8 | 1.8 | 99.9% | |
Inventory Days | Days | 10 | 111 | 8.7% | |
Debtors Days | Days | 7 | 124 | 5.5% | |
Net fixed assets | Rs m | 31,498 | 6,838 | 460.7% | |
Share capital | Rs m | 393 | 74 | 528.6% | |
Net worth | Rs m | 43,705 | 12,571 | 347.7% | |
Long term debt | Rs m | 0 | 4,418 | 0.0% | |
Total assets | Rs m | 60,637 | 23,747 | 255.3% | |
Interest coverage | x | 8.1 | -7.7 | -104.3% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 138.2% | |
Return on assets | % | 6.5 | -15.2 | -42.6% | |
Return on equity | % | 7.8 | -32.1 | -24.4% | |
Return on capital | % | 9.3 | -19.8 | -46.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 7,240 | 1,367 | 529.6% | |
From Investments | Rs m | -4,476 | -420 | 1,066.3% | |
From Financial Activity | Rs m | -2,620 | 4,009 | -65.3% | |
Net Cashflow | Rs m | 144 | 4,957 | 2.9% |
Compare ALEMBIC PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ALEMBIC PHARMA With: ASTRAZENECA PHARMA SURYA PHARMA PANCHSHEEL ORG VILIN BIO MED BETA DRUGS
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.